Companies › Erasca
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Naporafenib B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor | RAF1, BRAF | Phase 3 | Advanced or Metastatic NRAS-mutant Melanoma; Advanced or Metastatic Solid Tumors | Dec 2026 |
| ERAS-0015 RAS pathway inhibitor | – | Phase 1 | Metastatic Solid Tumors | May 2028 |
| ERAS-4001 KRAS inhibitor | KRAS | Phase 1 | Metastatic Solid Tumors | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05907304 | Naporafenib | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Dec 2026 |
| NCT06346067 | Naporafenib | Phase 3 | Advanced or Metastatic NRAS-mutant Melanoma | Oncology | Apr 2028 |
| NCT06983743 | ERAS-0015 | Phase 1 | Metastatic Solid Tumors | Oncology | May 2028 |
| NCT07021898 | ERAS-4001 | Phase 1 | Metastatic Solid Tumors | Oncology | Aug 2028 |
Cash and short-term investments of $384m on 2026-06-30; operating cash outflow about $111m a year; runway about 42 months at that burn, to Dec 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Sellas Life Sciences Group Kumquat Biosciences Genfleet Therapeutics (Shanghai) Revolution Medicines Vividion Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.